Adma Biologics (ADMA) Invested Capital (2011 - 2025)

Adma Biologics has reported Invested Capital for 15 years, with the latest figure at $480.1 million in Q4 2025.

• For the quarter ending Q4 2025, Invested Capital rose 37.57% year-over-year to $480.1 million; the trailing twelve-month figure through Dec 2025 stood at $480.1 million (up 37.57% YoY), and the FY2025 full-year result was $480.1 million, up 37.57% from the prior year.
• Invested Capital for Q4 2025 stood at $480.1 million, up from $433.5 million in the prior quarter.
• The five-year high for Invested Capital was $480.1 million in Q4 2025, with the low at $100.4 million in Q3 2022.
• Historically, Invested Capital has averaged $207.5 million across 5 years, with a median of $149.1 million in 2023.
• Annual changes were most pronounced in 2023 — Invested Capital declined 11.03% — and 2024, when it soared 158.14%.
• Adma Biologics' Invested Capital stood at $141.2 million in 2021, then rose by 7.65% to $152.0 million in 2022, then retreated by 11.03% to $135.2 million in 2023, then soared by 158.14% to $349.0 million in 2024, then surged by 37.57% to $480.1 million in 2025.
• The last three Invested Capital figures came in at $480.1 million (Q4 2025), $433.5 million (Q3 2025), and $398.3 million (Q2 2025), per Business Quant data.